Teva Pharmaceuticals presents eight studies at SIRS on UZEDY, an extended-release injectable risperidone for schizophrenia, focusing on dosing conversion and efficacy/safety.
Teva Pharmaceuticals showcases eight studies at SIRS, focusing on UZEDY, an extended-release injectable risperidone for adults with schizophrenia. The studies investigate dosing conversion strategies and efficacy/safety, with the aim of addressing limited clinical data on optimal LAI treatment switch strategies. PopPK modeling simulates switching from a biweekly intramuscular LAI formulation to UZEDY within 4-6 weeks.
April 06, 2024
3 Articles